help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FINK, J. B.
Right arrow Articles by TOBIN, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FINK, J. B.
Right arrow Articles by TOBIN, M. J.

Am. J. Respir. Crit. Care Med., Volume 159, Number 1, January 1999, 63-68

Reconciling In Vitro and In Vivo Measurements of Aerosol Delivery from a Metered-Dose Inhaler during Mechanical Ventilation and Defining Efficiency-enhancing Factors

JAMES B. FINK, RAJIV DHAND, JERRY GRYCHOWSKI, PATRICK J. FAHEY, and MARTIN J. TOBIN

Division of Pulmonary and Critical Care Medicine, Hines Veterans Administration Hospital, and Loyola University of Chicago Stritch School of Medicine, Hines, Illinois

We attempted to resolve the discrepancies in reported data on aerosol deposition from a chlorofluorocarbon (CFC)-propelled metered-dose inhaler (MDI) during mechanical ventilation, obtained by in vivo and in vitro methodologies. Albuterol delivery to the lower respiratory tract was decreased in a humidified versus a dry circuit (16.2 versus 30.4%, respectively; p < 0.01). In 10 mechanically ventilated patients, 4.8% of the nominal dose was exhaled. When the exhaled aerosol was subtracted from the in vitro delivery of 16.2% achieved in a humidified ventilator circuit, the resulting value (16.2 - 4.8 = 11.4%) was similar to in vivo estimates of aerosol deposition. Having reconciled in vitro with in vivo findings, we then evaluated factors influencing aerosol delivery. A lower inspiratory flow rate (40 versus 80 L/min; p < 0.001), a longer duty cycle (0.50 versus 0.25; p < 0.04), and a shorter interval between successive MDI actuations (15 versus 60 s; p < 0.02) increased aerosol delivery, whereas use of a hydrofluoroalkane (HFA)-propelled MDI decreased aerosol delivery compared with the CFC-propelled MDI. A MDI and actuator combination other than that designed by the manufacturer altered aerosol particle size and decreased drug delivery. In conclusion, aerosol delivery in an in vitro model accurately reflects in vivo delivery, providing a means for investigating methods to improve the efficiency of aerosol therapy during mechanical ventilation.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Dhand
Aerosol Therapy during Mechanical Ventilation: Getting Ready for Prime Time
Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1148 - 1149.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. L. GOODE, J. B. FINK, R. DHAND, and M. J. TOBIN
Improvement in Aerosol Delivery with Helium-Oxygen Mixtures during Mechanical Ventilation
Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 109 - 114.
[Abstract] [Full Text]

Home page
 ChestHome page
S. Nava and M. L. Compagnoni
Controlled Short-term Trial of Fluticasone Propionate in Ventilator-Dependent Patients With COPD
Chest, October 1, 2000; 118(4): 990 - 999.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. F. LANGE and W. H. FINLAY
Overcoming the Adverse Effect of Humidity in Aerosol Delivery via Pressurized Metered-Dose Inhalers during Mechanical Ventilation
Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1614 - 1618.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society 		  Solid Organ Transplant for the Intensivist 2008